Framingham Heart Study Gutted

The iconic Framingham Heart Study, the longest-running cardiovascular study in the country, has been hit with a $4 million budget cut.

Written byChris Palmer
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, HEIKENWAELDER HUGOThe 65-year-old Framingham Heart Study, which has studied the causes and effects of cardiovascular disease, is faced with $4 million in budget cuts due to sequestration. The cuts mean 19 of the 90 study staff members will lose their jobs, the Huffington Post reported. In addition, the cuts could mean that the next round of testing, to be conducted over the next two to three years, could be threatened.

“You’re going to lose a major investment that we’ve been making over the last 65 years,” Karen Antman, dean of Boston University School of Medicine, which co-runs the Framingham Heart Study, told the Huffington Post. “This is an iconic trial that has more than proven its value from a public health point of view.”

In 1948, the Framingham study began with funding from the National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH). Over the years, the cohort study has recruited more than 15,000 residents of Framingham, Mass., across three generations to help identify risk factors for diabetes, hypertension, hyperlipidemia, and other cardiovascular diseases. The Framingham study receives around $21 million in funding from the NIH annually, about ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies